The Best Dividend Stock to Own During a Market Crash

Kimberly-Clark offers a 5.2% dividend yield backed by a $5.12 annual payout and a 54-year streak of dividend increases, positioning it as a defensive name if markets weaken. The company also plans to acquire Kenvue for $48.7 billion, adding brands such as Tylenol, Neutrogena, and Listerine, though investors are concerned about dilution and the stock is still more than 30% below its high. Shares trade at 15x earnings versus a five-year average of 22x, suggesting limited downside but also reflecting merger-related caution.

Analysis

KMB is being priced less like a defensive staple and more like a leveraged integration story with a funding overhang. The key second-order effect is that the market is likely discounting not just dilution, but a period of subpar capital allocation where management will need to defend the dividend, absorb integration costs, and potentially sacrifice buybacks for 12-24 months. That creates a cleaner setup for relative outperformance in the rest of staples than for outright upside in KMB itself.

The main beneficiary of this reset is not just other household-purchase names, but any staple with stronger self-funded growth and cleaner balance sheet flexibility. If KMB has to preserve the payout while taking on a larger asset base, peers with room to increase repurchases or fund pricing actions without M&A drag should screen better on a 6-12 month basis. On the other side, KVUE holders face a deal-driven repricing event rather than a pure fundamentals trade: the market will likely focus on break-fee optionality and the probability of a reset in ownership structure rather than operating performance alone.

The contrarian read is that the downside may already be more limited than headline merger anxiety suggests, but the upside is also constrained because this is a low-growth category absorbing a large integration. In a risk-off tape, KMB should outperform on the first drawdown, but once volatility normalizes, investors may rotate toward higher-quality defensives with better free-cash-flow conversion and less M&A execution risk. The catalyst path is therefore binary: immediate support if markets weaken, but underperformance relative to staples if the deal closes and dilution becomes visible in per-share metrics over the next several quarters.

Key Decisions for Investors

• Long KMB vs. XLP or PG on a 3-6 month horizon only as a defensive beta hedge; target modest upside from flight-to-safety flows, but cap position size because integration/dilution can compress per-share value after close.
• Short KVUE into merger uncertainty or via call spreads if borrow is tight; the market is likely to reprice the stock on financing/dilution mechanics rather than operating fundamentals over the next 1-3 months.
• Pair trade: long PG or CL vs. short KMB for 6-12 months to express 'cleaner staple balance sheet' over 'staple with M&A hangover'; this captures relative multiple expansion if risk appetite stabilizes.
• If KMB sells off further on deal headlines, consider selling cash-secured puts 10-15% below spot for a 3-6 month tenor; the left-tail is increasingly limited, and carry is attractive if you are willing to own the name for yield.
• Avoid chasing KMB outright for total return: the risk/reward is skewed toward income, not multiple expansion, unless management can quickly demonstrate accretion or materially lower financing drag post-close.